Know Cancer

or
forgot password

Secondary Adult's Hemophagocytic Lymphohistiocytosis and Innate Immunity


N/A
18 Years
N/A
Open (Enrolling)
Both
Hemophagocytic Lymphohisticytosis

Thank you

Trial Information

Secondary Adult's Hemophagocytic Lymphohistiocytosis and Innate Immunity


Inclusion Criteria:



Patients Hemophagocytic lymphohisticytosis group:

- Of more than 18 years old

- affected by secondary LH infections with the exception of the HIV, the lymphomes, the
néoplasies or the autoimmunes / inflammatory diseases following the criteria of the
HLH Society modified in 2004

group control

- Of more than 18 years old

- At the time of the diagnosis either of firstly viral infection (EBV, CMV, parvovirus
B19, HSV), is of lymphome cunning(malignant) not - Hodgkinien or of epithelial
métastasés cancers, or auto-immune disease (erythemic lupus and disease of Still of
the adult only) without associated criteria corresponding to the diagnosis of LHS

- have agreed to benefit from a pregnancy test and from a screening sérologique by the
infection by the HIV. These tests that must be negative. In case of positivity of the
screening HIV, the patients will be directed to an adequate service.

- Have still received no preliminary treatment for this pathology

- Have agreed to participate in the study and to have signed the form of consent

group healthy control They will have to be unhurt of active infectious pathology,
hématologique, auto-immune or neoplastic and have by receipt of immunosuppresseurs
treatments during the last 2 years.

Exclusion Criteria:

Patients Hemophagocytic lymphohisticytosis group:

- Minor patients under age 18 or vulnerable (encircled women, private persons of
freedom judicially or administratively, adults under guardianship, under guardianship
and to express their consent)

- histories of established LHF or episode of LH during the childhood

- patients reached(affected) by infection by the HIV: either histories known for
seropositivity and / or of disease, or because of the positivity of the test
sérologique realized in the inclusion after consent of the patient.

- Have already benefited from a specific treatment of the LHS

group control

Patients under age 18 and not to belong in one group of vulnerable persons (encircled
women, private persons of freedom judicially or administratively, adults under
guardianship, under guardianship and to express their consent)

- Patients answering the criteria of diagnosis of LHS

- Patients having already had histories of LH

- Patients having already received the specific treatments of these diseases

- patients reached(affected) by infection by the HIV: either histories known for
seropositivity and / or of disease, or because of the positivity of the test
sérologique realized in the inclusion after consent of the patient.

group healthy control Patients under age 18 and not to belong in one group of vulnerable
persons (encircled women, private persons of freedom judicially or administratively,
adults under guardianship, under guardianship and to express their consent)

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science

Outcome Measure:

the cytotoxicité lymphocytaire

Outcome Description:

To compare the cytotoxicité lymphocytaire at the patients affected by LHS with regard to 2 groups of subjects controls: a group of patients affected by infections except HIV, by hémopathies or by epithelial métastasés cancers, by autoimmunes / inflammatory pathologies (spread erythemic lupus and disease of Still of the adult) but having no LHS (controls-patients) and a group of healthy subjects.

Outcome Time Frame:

3 years

Safety Issue:

No

Principal Investigator

jean robert HARLE

Investigator Role:

Principal Investigator

Investigator Affiliation:

Assistance Publique Hopitaux De Marseille

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

2007/35

NCT ID:

NCT01125319

Start Date:

March 2010

Completion Date:

September 2013

Related Keywords:

  • Hemophagocytic Lymphohisticytosis
  • Lymphohistiocytosis, Hemophagocytic

Name

Location